ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Cancer Control Survey “a Flop,” Advisory committee Members Say

October 11, 1974

In Brief: XIIIth Congress Draws Record Number Of Abstracts, 3,000 Registrants So Far; Exhibit Area Sold Out

March 5, 1982

Professional Societies: ASCO opposes FDA On Stem Cell Transplant Regs

May 16, 1997

DCT Advisors Approve Increased Spending On Trials Monitoring

May 6, 1994

A Conversation with MSKCC’s José Baselga: We Need to Increase Our Reach

September 27, 2013

FDA Approves Afinitor Tablets For Advanced Breast Cancer

August 31, 2012